Literature DB >> 32413212

S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update.

Enno Schmidt1,2, Michael Sticherling3, Miklós Sárdy4, Rüdiger Eming5, Matthias Goebeler6, Michael Hertl5, Silke C Hofmann7, Nicolas Hunzelmann8, Johannes S Kern9, Harald Kramer10, Alexander Nast11, Hans-Dieter Orzechowski12,13, Christiane Pfeiffer14, Volker Schuster15, Cassian Sitaru9, Miriam Zidane11, Detlef Zillikens1, Margitta Worm16.   

Abstract

Year:  2020        PMID： 32413212     DOI： 10.1111/ddg.14097

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN： 1610-0379            Impact factor:   5.584


× No keyword cloud information.
  10 in total

1.  Methylprednisolone Plus Low-Dose Methotrexate for Bullous Pemphigoid-A Single Center Retrospective Analysis.

Authors:  Agoritsa Gravani; Georgios Gaitanis; Panagiota Spyridonos; Ioannis Alexis; Stelios Tigas; Ioannis D Bassukas
Journal:  J Clin Med       Date:  2022-06-02       Impact factor: 4.964

2.  Pemphigus Foliaceus Autoantibodies Induce Redistribution Primarily of Extradesmosomal Desmoglein 1 in the Cell Membrane.

Authors:  Matthias Hiermaier; Daniela Kugelmann; Mariya Y Radeva; Dario Didona; Kamran Ghoreschi; Solimani Farzan; Michael Hertl; Jens Waschke
Journal:  Front Immunol       Date:  2022-05-12       Impact factor: 8.786

3.  Survival of Adjuvant Drugs for Treatment of Pemphigus: A Population-based Cohort Study.

Authors:  Khalaf Kridin; Christoph M Hammers; Ralf J Ludwig; Dana Tzur Bitan; Arnon D Cohen
Journal:  Acta Derm Venereol       Date:  2021-09-03       Impact factor: 3.875

4.  Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity.

Authors:  Maike M Holtsche; Nina van Beek; Takashi Hashimoto; Giovanni Di Zenzo; Detlef Zillikens; Catherine Prost-Squarcioni; Matthias Titeux; Alain Hovnanian; Enno Schmidt; Stephanie Goletz
Journal:  Acta Derm Venereol       Date:  2021-03-23       Impact factor: 3.875

5.  Plasmapheresis: a feasible choice for bullous pemphigoid patients infected with SARS-CoV-2.

Authors:  Yu Cui; Caixia Hu; Yi Cheng; Xiaomei Han; Wenqing Wang
Journal:  Int J Dermatol       Date:  2021-09-14       Impact factor: 3.204

6.  Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid-A Retrospective, Monocentric Study.

Authors:  Franziska Schauer; David Rafei-Shamsabadi; Shoko Mai; Yosuke Mai; Kentaro Izumi; Frank Meiss; Dimitra Kiritsi
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

Review 7.  Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders.

Authors:  Bianca Opelka; Enno Schmidt; Stephanie Goletz
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

8.  Severe Bullous Pemphigoid Onset after Jugular Catheter Placement in a Patient on Hemodialysis.

Authors:  Lucas Jacobs; Francesco Feoli; Pascal Bruderer; Semra Top; Ivan Grozdev; Edouard Cubilier; Frederic Collart
Journal:  Case Rep Nephrol Dial       Date:  2022-08-29

Review 9.  Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.

Authors:  Nina van Beek; Detlef Zillikens; Enno Schmidt
Journal:  Dtsch Arztebl Int       Date:  2021-06-18       Impact factor: 8.251

10.  [Approved systemic therapies in dermatology].

Authors:  Monika Kleinhans; Carolin Funke-Lorenz; Joachim Dissemond
Journal:  Hautarzt       Date:  2021-04-21       Impact factor: 0.751
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.